Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 325

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

The overlooked pandemic of antimicrobial resistance

Open access
Laxminarayan, Ramanan·2022·The Lancet

Abstract

As COVID-19 rages on, the pandemic of antimicrobial resistance (AMR) continues in the shadows. The toll taken by AMR on patients and their families is largely invisible but is reflected in prolonged bacterial infections that extend hospital stays and cause needless deaths. Moreover, AMR disproportionately affects poor individuals who have little access to second-line, more expensive antibiotics that could work when first-line drugs fail. Previous attempts have been made to accurately estimate the global burden of AMR, both to focus policy makers on the extent of the problem and to identify geographical areas with the greatest burden. These estimates have been challenged by unreliable data on resistance and infections and the difficulty of attributing burden to AMR specifically. Patients with longer hospitals stays are more likely to have resistant pathogens than those with shorter stays. Is it AMR that causes these longer hospital stays or is it just that patients who stay longer happen to pick up drugresistant infections? How can we distinguish between patients who died with resistant pathogens from those who died of resistant pathogens? In The Lancet, Christopher Murray and colleagues present their ambitious effort to address the question of the global burden of AMR. The authors estimated disease burden for 23 pathogens and 88 pathogen– drug combinations in 204 countries and territories in 2019 on the basis of two counterfactual scenarios: one in which all drug-resistant infections were replaced by drug-susceptible infections, and one in which all drugresistant infections were replaced by no infection. Using this method, the study directly addresses the difference between burden associated with resistance, and burden attributable to resistance. Murray and colleagues estimated a median of 1·27 million (95% uncertainty interval 0·911–1·71) deaths in 2019 directly attributable to resistance, a value that is nearly the same as global HIV deaths (680 000) and malaria deaths (627 000) combined, and ranks behind only COVID-19 and tuberculosis in terms of global deaths from an infection. The study’s estimate of 4·95 million (3·62–6·57) deaths associated with bacterial AMR globally in 2019 indicates that there are substantial gains to be made from preventing infections in the first place. Of the major bacterial pathogens covered in this study, only pneumococcal pneumonia is preventable through vaccination. Preventive vaccines against viral pathogens including influenza, respiratory syncytial virus, and rotavirus could be effective in reducing the need for treatment, thereby reducing inappropriate antibiotic consumption. In high-income countries, improved water and sanitation, public health, and hospital hygiene have been the primary ways in which infections have been controlled, but these methods have been difficult to implement in resource-poor settings despite economic progress. Ironically, the burden of resistance partly reflects the insufficient access to antibiotics. The problem of excessive and inappropriate use of antibiotics co-exists with the problem of insufficient access even in the same geographical areas. Pneumococcal pneumonia is easily treatable with antibiotics, but the burden estimated by Murray and colleagues reflects the lack of access to even inexpensive drugs such as penicillin. Some of the AMR burden in sub-Saharan Africa is probably due to inadequate access to antibiotics and high infection levels, albeit at low levels of resistance, whereas in south Asia and Latin America, it is because of high resistance even with good access to antibiotics. Over two-thirds of attributable deaths were due to resistance to first-line antibiotics including fluoroquinolones and β-lactam antibiotics (carbapenems, cephalosporins, and penicillins). Published Online January 20, 2022 https://doi.org/10.1016/ S0140-6736(22)00087-3

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(22)00087-3

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Cited by

See all 325

Metadata

Authors
Laxminarayan, R.
Venue
The Lancet
Publisher
Elsevier BV
Published
2022-02
Volume
399
Issue
10325
Pages
606-607
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W4205969323
Cited by
325
References
10
FWCI
27.31
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The overlooked pandemic of antimicrobial resistance. https://app.cochat.ai/papers/10.1016/s0140-6736(22)00087-3
The paper
Laxminarayan, R. (2022). The overlooked pandemic of antimicrobial resistance. The Lancet. https://doi.org/10.1016/s0140-6736(22)00087-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.